EPRX Reports 24-Week Symptom Response in RESOLVE Trial, 76% Clinical Remission, 4-Point SDI Reduction, No SAEs, 220+ Patient-Months
Eupraxia Pharmaceuticals Inc. Common Stock · Now $6.86
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS